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Abstract: Hepatocellular carcinoma (HCC) is the fifth commonest cancer worldwide. Vascular invasion of the portal vein 
is one of the most important prognostic factors for survival in HCC patients and the prognosis is generally poor. The 
optimal treatment for patients with HCC and portal vein tumour thrombus (PVTT) remains controversial. Although many 
therapeutic options have been proposed, surgical resection is the only hope of cure for such patients. 
We present the case of a 74-year-old man diagnosed with a single HCC nodule with portal thrombosis in the right 
hepatic lobe in the setting of HCV-related liver cirrhosis. After a first approach with a loco-regional treatment not tolerated 
by the patient, a right hepatectomy proved the best option. One year later the patient is still free from disease.  
Keywords: Hepatocellular carcinoma, Portal vein thrombosis, Liver resection. 
INTRODUCTION 
Hepatocellular carcinoma (HCC) is the fifth common 
cancer worldwide and the third cause of cancer-related 
death [1]. Portal vein tumour thrombosis (PVTT) is one 
of the principal factors influencing the prognosis of 
HCC as it is linked to an increased risk of intrahepatic 
and systemic metastases and shorter survival [2, 3]. 
PVTT is found in about 40-90% of patients at the first 
diagnosis of HCC [4].  
Cheng et al. divided PVTT into four types based on 
tumour site and extent: the segmental or sectoral 
branches of the portal vein (type I), the right/left portal 
vein (type II), the main portal vein trunk (type III), or the 
superior mesenteric vein (type IV) [5].  
The prognosis of patients with PVTT is generally 
poor with a median survival of 2.7-4 months in 
untreated cases [6]. PVTT remains one of the major 
contraindications to liver transplantation in patients with 
HCC due to the scarcity of organs and the high rate of 
tumour recurrence. Hepatic resection represents the 
only therapeutic alternative in these patients [7]. 
However, there is still no universal consensus on the 
best treatment for HCC with PVTT. 
We describe a patient with HCV-related HCC 
complicated by PVTT successfully treated by right 
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CASE REPORT 
A 74-year-old man was found to have hepatocellular 
carcinoma (HCC) with PVTT ten years after being 
diagnosed with liver cirrhosis due to hepatitis C virus. A 
computed tomography (CT) scan in 2012 showed a 30 
mm nodule of HCC in the subdiaphragmatic surface of 
the VIII hepatic segment, invasion of the portal 
segmental branches in the right lobe, but no disease in 
lymph nodes or any other sites. Laboratory tests were 
as follows: alpha-fetoprotein (AFP) 2527 ng/ml (n.v. 0-
10), aspartate aminotransferase (AST) 93 U/L (n.v. 0-
40), alanine aminotransferase (ALT) 95 U/L (n.v. 0-40), 
gamma-glutamyl transpeptidase (GGT) 165 U/L (n.v. 8-
61). The patient underwent percutaneous ethanol 
injection, but it was not tolerated and he asked to 
suspend the treatment.  
Because of the limited extent of the cancer, hepatic 
resection was the surgical management of choice. 
Right hepatectomy was performed with total removal of 
the portal thrombosis. Macroscopic examination of the 
tumour on the cut specimen showed a 4.5  3.5 cm 
yellowish necrotic lesion with a fibrous capsule. 
Microscopically, haematoxylin and eosin staining 
demonstrated the tumour consisted of a solid 
trabecular structure with extensive coagulative and 
colliquative necrosis. In addition, histopathological 
examination showed Edmondson G3 HCC, 
macroscopic and microscopic intra and peritumoral 
vascular thrombosis, and neoplastic thrombosis in the 
portal vein and its main perihilar branches. 
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The development of ascites complicated the 
postoperative course but resolved during a two-week 
hospital stay.  
Three months after surgery, laboratory data showed 
a substantial normalization of hepatic markers: GOT 48 
U/L, GPT 38 U/L, GGT 64 U/L, AFP 6.47 ng/ml. 
Abdominal ultrasound and thoraco-abdominal-pelvic 
CT evaluation showed no disease progression. On the 
basis of the radical surgical resection and the patient’s 
good clinical status, no adjuvant chemotherapy was 
administered to prevent HCC recurrence. After 16 
months of follow-up, the patient is still free from 
disease.  
DISCUSSION 
The potentially radical treatment options for patients 
with HCC include surgical resection, liver 
transplantation and loco-regional therapies depending 
on tumour staging and liver function. Both the 
European Association for the Study of the Liver (EASL) 
and the American Association for the Study of Liver 
Disease (AASLD) guidelines consider hepatic resection 
the treatment of choice for patients with preserved liver 
function and resectable HCC [8, 9]. However, only 10-
30% of cases of HCC patients are eligible for surgical 
treatment at the time of diagnosis [10, 11]. 
PVTT is a negative prognostic factor for 
hepatocellular carcinoma because of the increased risk 
of intrahepatic and systemic metastases, and the 
progressive deterioration of liver function. According to 
a US study, the median survival of patients with HCC 
and PVTT was 2.7 months if left untreated vs. 24.2 
months for those without PVTT [6].  
The management of HCC with PVTT is complicated 
and controversial. According to EASL/AASLD 
guidelines, these patients are only candidates for non-
curative treatment due to their poor prognosis and the 
post-operative risk of liver failure [8, 9]. PVTT 
represents one of the principal contraindications to liver 
transplantation due to the risk of early recurrence and 
the shortage of donors [12]. Several studies show a 
high response rate after loco-regional treatment in 
patients with HCC and PVTT, but their median survival 
time is <12 months [13, 14, 15, 16].  
Transcatheter arterial chemoembolization (TACE) is 
an alternative therapeutic option in patients with 
advanced HCC [8, 9] but PVTT is usually considered a 
contraindication. TACE may be performed in these 
patients if their liver function is sufficiently preserved 
but the long-term outcomes of HCC with PVTT are 
generally poor [17, 18]. Georgiades et al. Showed a 
median survival of 9.9 months in patients with HCC and 
PVTT undergoing TACE [19]. Peng et al compared the 
outcomes of 603 patients with HCC and PVTT treated 
with TACE or liver resection. They found a better 
median survival for HCC and PVTT undergoing surgery 
compared to TACE (20 vs. 13.1 months), especially for 
types I or II PVTT [20]. 
Considering the limitations of non-surgical 
management, liver resection represents the only radical 
treatment in HCC patients with PVTT.  
Recent studies have shown favorable long-term 
survival after surgical resection in well-selected cases 
of HCC with PVTT. Shi et al. evaluated outcomes after 
partial hepatectomy with or without thrombectomy in 
406 patients with HCC and PVTT. Patients with types I 
and II portal vein thrombosis had better overall survival 
(OS) than those with types III and IV [21]. The same 
findings were reported in a recent study by Chen et al. 
where HCC with PTVV extending into the main portal 
venous trunk had a worse median overall survival 
worse than patients with types I or II PVTT (3-year OS 
was 5.7% and 22.7%, respectively) [22]. 
Our report describes the case of a 74-year-old man 
diagnosed with a single nodule of HCC with PVTT in 
the right hepatic lobe. According to Cheng et al.’s 
classification of portal vein thrombosis, our patient had 
type II PVTT [5]. Given the location and extent of 
PVTT, he underwent right hepatectomy with total 
removal of the portal thrombosis. Three months after 
surgery, there was a substantial normalization of 
hepatic markers and abdominal CT did not show any 
progression of disease. One year later, the patient is 
still disease-free.  
The location and extent of vascular thrombosis are 
the principal factors influencing the choice of therapy 
and the prognosis of patients with HCC [2, 3]. Thrombi 
in extrahepatic locations or in the suprahepatic veins 
warrant different treatment strategies with proven 
efficacy and safety. 
Two patients with HCC and PVTT extending into the 
right atrium followed at our centre obtained a survival 
benefit (OS > 18 months) with good clinical condition 
after systemic treatment alone (sorafenib and 
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antiangiogenetic drugs). The current patient received 
an antithrombotic prophylaxis (low molecular weight 
heparin) to prevent venous thrombosis as the protocol 
for general surgical procedures. 
Patients with chronic liver disease have an impaired 
production of natural anticoagulant proteins, potentially 
increasing the risk of thrombotic events. However, the 
efficacy and safety of pharmacological prophylaxis in 
these patients is still a matter of debate. Villa et al. 
demonstrated the safety and the efficacy of a treatment 
with enoxaparin to reduce risk of portal vein thrombosis 
in a cohort of cirrhotic patients without HCC: patients 
treated with anticoagulants performed better in terms of 
liver function and OS [23]. 
To our knowledge, no guidelines are available on 
the use of venous thrombosis prophylaxis in cirrhotic 
patients. A study by Vivarelli et al. showed that 
anticoagulant prophylaxis is a safe option in patients 
without oesophageal varices undergoing hepatic 
resection. However, prophylaxis should be avoided in 
patients with a high risk of bleeding [24]. 
The present case demonstrates that liver resection 
is justified in selected patients with types I and II PVTT 
and offers a good long-term outcome for resectable 
HCC. By contrast, the benefit of surgery is less clear 
when the PVTT extends into the main portal vein or 
beyond. Thrombectomy has been proposed as a 
feasible treatment option if the tumour thrombus does 
not infiltrate the portal venous wall [21] but did not 
improve the survival rate for these patients compared 
with TACE. Further clinical studies are required. 
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